Type 2 Diabetes

Clinical Case Study: Managing Type 2 Diabetes with coMra Therapy

A 60-year-old female patient presented with a history of Type 2 diabetes spanning more than 25 years. Despite adhering to a recommended diet and maintaining regular consultations with general practitioners and endocrinologists, her condition remained poorly controlled. She reported a significant increase in daily blood glucose levels, ranging from 280 to 360 mg/dL, accompanied by persistent weakness, frequent dry mouth, and nocturia (frequent nighttime urination, occurring four to five times per night).

Upon clinical examination, the patient presented with a deterioration of vision and a subconjunctival hemorrhage in the left eye that had occurred the previous day. Her primary diagnoses included Type 2 diabetes with uncontrolled glycemia, diabetic sensory neuropathy of the lower extremities, diabetic angiopathy of both eyes, and diabetic nephropathy. Additionally, she was diagnosed with pyelonephritis in a state of latent inflammation and chronic cholecystitis. At the time of presentation, her medication regimen consisted of Metformin (1000 mg twice daily) and Diabeta (3.5 mg twice daily).

The coMra Treatment Protocol

The patient underwent a structured course of coMra therapy consisting of 11 treatments, scheduled at a frequency of two treatments per day. Throughout this period, she maintained her existing hypoglycemic medication dosages.

Clinical Outcomes and Observations

Following the initial 11-treatment cycle, the patient experienced significant improvements across several health markers:

* Glycemic Control: Blood glucose levels stabilized between 145 and 200 mg/dL, a marked improvement from her previous baseline of approximately 340 mg/dL, achieved while maintaining the same medication dosage. * Symptom Relief: The patient reported that her chronic dry mouth and excessive thirst had completely disappeared. * Ocular Health: The subconjunctival hemorrhage in the left eye resolved within three to four days. * Cardiovascular and Systemic Health: Blood pressure improved from 150/90 mmHg to 130/80 mmHg. Furthermore, the patient noted that her sleep patterns normalized, and symptoms of depression subsided. * Urinary Function: Nocturia decreased significantly, with the patient reporting only one instance of nighttime urination.

Long-Term Management Recommendations

To sustain these results, it was recommended that the patient continue with a structured coMra therapy regimen. The proposed plan includes a second 11-treatment cycle after a one-to-two-week interval, followed by a three-week break. Subsequently, the patient is advised to follow a course of 22 treatments without breaks throughout the year.

This adapted course should be repeated one to two times per quarter. Should the patient’s glucose levels rise to between 140 and 180 mg/dL, a gradual reduction of her hypoglycemic medication may be considered under medical supervision as her body’s own healing capacity continues to be supported by coMra therapy.